世界の内分泌検査市場の規模、シェア、トレンド分析レポート – 業界の概要と2032年までの予測

Get Exclusive Sample PDF of this Report Here

内分泌検査市場分析

内分泌検査市場は、高度な診断技術と革新的な検査方法の発展により、著しい成長を遂げています。自動免疫測定法と化学発光免疫測定法 (CLIA) は、ホルモンの不均衡を検出する際の精度とスピードから、ますます採用が進んでいます。さらに、液体クロマトグラフィータンデム質量分析法(LC-MS/MS) は、特に副腎機能不全や甲状腺疾患などの複雑な症状に対して、正確で感度の高いホルモン分析のゴールドスタンダードとなっています。

ウェアラブルバイオセンサーは、グルコースやコルチゾールレベルなどの内分泌パラメータをリアルタイムで監視できる革新的なツールとして登場しています。遠隔医療の統合により、特に遠隔地での内分泌検査へのアクセスがさらに拡大し、早期診断と治療結果が向上しました。

この市場の成長は、糖尿病、肥満、甲状腺機能障害などの内分泌関連疾患の増加によって推進されています。新興経済国における意識の高まりと技術導入と相まって、生活習慣病の罹患率が増加し、市場の拡大を支えています。政府の取り組みや医療提供者間の戦略的パートナーシップも、世界的に内分泌診断の進歩に貢献しています。

内分泌検査市場規模

世界の内分泌検査市場規模は、2024年に113億9,000万米ドルと評価され、2025年から2032年の予測期間中に5.88%のCAGRで成長し、2032年までに179億9,000万米ドルに達すると予測されています。市場価値、成長率、セグメンテーション、地理的範囲、主要プレーヤーなどの市場シナリオに関する洞察に加えて、Data Bridge Market Researchがまとめた市場レポートには、詳細な専門家分析、患者の疫学、パイプライン分析、価格分析、規制枠組みも含まれています。

内分泌検査市場の動向

「家庭用検査キットの導入増加」

内分泌検査市場の成長を牽引している特定の傾向の1つは、在宅検査キットの採用の増加です。これらのキットを使用すると、ユーザーは自宅で便利にコルチゾール、テストステロン、甲状腺ホルモンなどのホルモンレベルを測定でき、プライバシーと使いやすさを提供します。EverlywellやLetsGetCheckedなどの企業は、セルフケアとリモートヘルスケアの好みの高まりに対応し、迅速な結果をもたらすアクセス可能なソリューションを開発しました。COVID-19パンデミックにより、患者がクリニックでの診察に代わる方法を求めたことから、この傾向が加速しました。さらに、スマートフォン統合診断デバイスなどのテクノロジーの進歩により、これらのキットの精度と使いやすさが向上し、内分泌検査がよりアクセスしやすくなり、世界的に市場拡大が促進されています。

レポートの範囲と内分泌検査市場のセグメンテーション  

Get Exclusive Sample PDF of this Report Here

内分泌検査市場の定義

内分泌検査は、甲状腺、副腎、膵臓、下垂体などの腺を含む内分泌系の機能を評価します。これらの検査では、血液、尿、唾液中のホルモン濃度を測定し、糖尿病、甲状腺疾患、副腎機能不全、ホルモン不均衡などの症状を診断します。一般的な検査には、甲状腺機能検査(TSH、T3、T4)、糖尿病の耐糖能検査、ストレス反応のコルチゾール測定などがあります。内分泌検査は、代謝、成長、生殖、および全体的な健康に影響を与えるホルモンの問題を特定するために不可欠です。検査技術の最新の進歩により、正確で早期の診断が保証され、内分泌関連疾患の効果的な治療と管理に役立ちます。

内分泌検査市場の動向

ドライバー

• 内分泌疾患の有病率の上昇

糖尿病、甲状腺機能不全、副腎疾患などの内分泌疾患の罹患率の上昇により、内分泌検査の需要が大幅に増加しています。たとえば、世界保健機関 (WHO) の報告によると、糖尿病は世界中で 4 億人以上に影響を与えており、診断されていない症例も多く、血糖値とホルモン レベルを監視するための診断検査の必要性が高まっています。同様に、甲状腺疾患、特に甲状腺機能低下症は、特に高齢者で増加しています。これらの症状には、ホルモンの不均衡を効果的に管理するための定期的な検査が必要です。その結果、これらの疾患の診断率の上昇により、世界中の医療現場で正確でアクセスしやすく、タイムリーな内分泌検査の需要が高まり、市場の成長を後押ししています。

• 診断検査室の拡張

特に発展途上地域での診断ラボチェーンの拡大は、内分泌検査市場の成長に大きく貢献しています。インドやブラジルなどの国では、診断センターの数が増えており、内分泌検査がより身近で手頃な価格になっています。たとえば、米国の大手企業であるLabcorpやQuest Diagnosticsは、ホルモン検査の需要の高まりに対応するために国際的に事業を拡大しています。インドでは、Dr. Lal PathLabsやThyrocareなどの診断会社が都市部と農村部の両方で存在感を高め、手頃な価格の内分泌検査サービスを提供しています。このアクセスのしやすさにより、患者の意識が高まり、早期発見が容易になり、診断検査の需要が世界的に高まります。

機会

• ホルモンの不均衡に対する意識の高まり

The increasing public awareness of hormonal imbalances has created significant opportunities in the endocrine testing market. Educational campaigns and health programs, especially those targeting conditions such as thyroid dysfunction, diabetes, and polycystic ovary syndrome (PCOS), have empowered individuals to recognize symptoms and seek timely testing. For instance, the American Thyroid Association’s initiatives have raised awareness of thyroid disorders, leading to higher testing rates. As people become more proactive in managing their health, there is a growing demand for hormone level assessments, offering a lucrative opportunity for companies providing advanced diagnostic solutions. This trend is expected to drive market growth in the coming years.

• Integration of Artificial Intelligence

The integration of Artificial Intelligence (AI) in endocrine testing presents a significant opportunity for the market by enhancing the precision and efficiency of diagnostics. AI-powered platforms are capable of analyzing complex hormone test results faster and more accurately than traditional methods, which can improve diagnostic accuracy and treatment outcomes. For instance, AI algorithms can detect patterns in data from thyroid function tests, such as TSH, T3, and T4 levels, to identify early signs of thyroid disorders such as hypothyroidism or hyperthyroidism. This not only reduces human error but also speeds up diagnosis, making it an attractive option for healthcare providers. As a result, AI’s growing adoption in healthcare offers substantial growth potential in the endocrine testing market.

Restraints/Challenges

• High Price of Testing

The advanced testing procedures and specialized equipment required for accurate endocrine testing can be prohibitively expensive. This presents a significant challenge, particularly in low-income regions and healthcare settings with limited budgets. The high costs not only restrict access to these vital tests for many patients but also place a burden on healthcare providers, forcing them to prioritize other essential services. As a result, the demand for endocrine testing may remain low in underserved areas, slowing the overall market growth. The financial barriers further exacerbate health disparities, limiting the ability of many individuals to undergo timely diagnostic tests for endocrine disorders.   

• Lack of Standardization

The lack of standardization in the endocrine testing market presents a significant challenge. Variability in testing methods, equipment, and protocols across different regions or institutions results in inconsistent testing procedures, leading to discrepancies in results. This lack of uniformity complicates the interpretation of test outcomes, potentially impacting diagnostic accuracy and patient care. Furthermore, without standardized practices, it becomes difficult to compare results from different laboratories, hindering the development of universal treatment guidelines. These inconsistencies create uncertainty in the reliability of tests, which can deter healthcare providers and patients from fully embracing endocrine testing, ultimately limiting market growth and adoption.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Endocrine Testing Market Scope

The market is segmented on the basis of test, technology and end users. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Test

• Thyroid Test
• Insulin Test
• Dehydroepiandrosterone sulfate (DHEAS)
• Human Chorionic Gonadotropin Test
• Human Chorionic Gonadotropin (HCG)
• Follicle Stimulating (FSH)
• Prolactin Test
• Luteinizing Hormone Test
• Progesterone Test
• Others

Technology

• Immunoassay
• Monoclonal and Polyclonal Antibody Technologies
• Clinical Chemistry Technologies
• Tandem Mass Spectroscopy
• Sensor Technology
• Others

 End-User

• Hospitals
• Clinical Laboratories
• Others

Endocrine Testing Market Regional Analysis

The market is analysed and market size insights and trends are provided by country, test, technology and end users as referenced above.

The countries covered in the market report are U.S., Canada, Mexico in North America, Germany, Sweden, Poland, Denmark, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe in Europe, Japan, China, India, South Korea, New Zealand, Vietnam, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), Brazil, Argentina, Rest of South America as a part of South America, U.A.E, Saudi Arabia, Oman, Qatar, Kuwait, South Africa, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA)

North America is expected to dominate the endocrine testing market due to the high prevalence of obesity, increasing awareness about endocrine disorders, and advancements in diagnostic technologies. In addition, the development of innovative, easy-to-operate test kits contributes significantly to the region's market growth.

Asia-Pacific is expected to show growth in the endocrine testing market during the forecast period due to the rising prevalence of endocrine disorders. In addition, government initiatives aimed at enhancing healthcare facilities and increasing patient awareness are driving demand for advanced diagnostic solutions.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Endocrine Testing Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Endocrine Testing Market Leaders Operating in the Market Are:

• Abbott (U.S.)
• DH Tech. Dev. Pte. Ltd. (Singapore)
• Biomedical Technologies Limited (U.K.)
• Agilent Technologies (U.S.)
• Beckman Coulter, Inc. (U.S.)
• bioMérieux SA (France)
• Bio-Rad Laboratories Inc. (U.S.)
• DiaSorin (Italy)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Laboratory Corporation of America Holdings (U.S.)
• Quest Diagnostics Incorporated (U.S.)
• Hologic, Inc. (U.S.)
• Ortho Clinical Diagnostics (U.S.)
• QIAGEN (Germany)
• American Chemistry Council, Inc. (U.S.)

Latest Developments in Endocrine Testing Market

• In November 2023, The FDA approved Eli Lilly’s Zepbound (tirzepatide) injection as the first obesity treatment targeting both GIP and GLP-1 hormone receptors. This groundbreaking drug is indicated for adults with obesity or overweight, particularly those with related medical conditions. When combined with a reduced-calorie diet and increased physical activity, Zepbound aids in significant weight loss, offering a novel solution for managing obesity
• In October 2023, Eli Lilly and Company presented results from two Phase 3 trials, LIBRETTO-431 and LIBRETTO-531, at the ESMO Congress 2023. These trials evaluated Retevmo (selpercatinib) in RET fusion-positive non-small cell lung cancer (NSCLC) and RET-mutant medullary thyroid cancer (MTC). In both cases, Retevmo demonstrated promising efficacy, outperforming chemotherapy and multi-kinase inhibitors, making it a promising treatment for these advanced cancers
• In April 2023, Eli Health raised USD 3.6 million to develop saliva-based continuous hormone monitoring technology. Initially focusing on menopause, fertility, and general health, the technology aims to empower women with real-time insights into their hormonal health. Future expansion plans include addressing contraception and endocrine diseases once regulatory approvals and clinical validations are completed, potentially transforming women's health monitoring
• In August 2022, The FDA approved the Mira Ovum Wand, an over-the-counter device that detects follicle-stimulating hormone (FSH) levels in urine. This tool enables women to monitor their fertility at home with ease and accuracy. The Mira Ovum Wand offers a new, accessible option for women tracking ovulation, helping with family planning and improving overall reproductive health management
• In May 2022, Inne.io, based in Berlin, secured an additional EUR 9.3 million to expand its hormone-tracking technology. This funding aims to help women better understand and manage their reproductive health. The company focuses on providing accessible hormone tracking solutions, with plans to eventually broaden its offerings to include other areas such as fertility and contraception, potentially revolutionizing the way women track their hormonal health
• In March 2021, Abbott Laboratories launched the Alinity m Diagnostics System, a high-throughput, automated platform for immunoassay testing. The system enables rapid and accurate diagnostic testing for endocrine-related conditions and other medical tests. With its quick turnaround time and advanced technology, the Alinity m system significantly improves diagnostic efficiency, enhancing Abbott’s position in the medical diagnostics market and contributing to improved patient care
• 2021年2月、シーメンス ヘルシニアーズは、包括的で完全に自動化された免疫測定システムである内分泌学向けアテリカ ソリューションを発表しました。内分泌学検査用に設計されたこのシステムは、幅広いホルモンマーカーに対して正確で信頼性の高い結果を提供します。アテリカ ソリューションの発売により、シーメンスの製品ポートフォリオが強化され、ヘルスケア分野における正確で自動化された検査ソリューションに対する高まる需要に応える能力が向上しました。

SKU-65501